



Skeletal mass indices are inversely associated with metabolically unhealthy phenotype in overweight/obese and normal-weight men: a population-based cross-sectional study

Cristiane Junqueira de Carvalho^{1,2*}, Giana Zarbato Longo^{2,3}, Adriana Maria Kakehasi⁴,
Patrícia Feliciano Pereira², Kátia Josiany Segheto², Leidjaira Lopes Juvanhol² and Andréia Queiroz Ribeiro²

¹Department of Medicine and Nursing, Federal University of Viçosa (UFV), Viçosa, Minas Gerais, 36570-900, Brazil

²Postgraduate Program in Nutrition Science, Department of Nutrition and Health, Federal University of Viçosa (UFV), Viçosa, Minas Gerais, 36570-900, Brazil

³Postgraduate Program in Nutrition, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, 88040-900, Brazil

⁴Department of the Locomotor Apparatus, Medical School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, 30130-100, Brazil

(Submitted 16 May 2020 – Final revision received 18 October 2020 – Accepted 26 October 2020 – First published online 4 November 2020)

Abstract

Muscle mass may play an important role in the metabolic profile of individuals with or without excess weight. Metabolic phenotypes classify individuals as healthy or unhealthy based on certain metabolic conditions. We investigated the association between skeletal mass indices (SMI) and the metabolically unhealthy phenotype in normal-weight and overweight/obese adults. A total of 660 adults aged 20 to 59 years were assessed by a population-based cross-sectional study. Muscle mass of the limbs or appendicular lean mass (ALM) adjusted for weight (SMI_{weight}) and BMI (SMI_{BMI}) was used to evaluate SMI. Logistic regression was employed to estimate the association between SMI_{weight}, SMI_{BMI} and metabolic phenotypes of normal-weight and overweight/obese individuals. Metabolically unhealthy individuals were older in both sexes. Metabolically unhealthy men had lower SMI values and higher fat percentage than metabolically healthy men. SMI_{weight} was inversely associated with the metabolically unhealthy phenotype, both in normal-weight men (OR 0.49, 95 % CI 0.24, 0.99, $P = 0.04$) and in overweight/obese men (OR 0.32, 95 % CI 0.16, 0.64, $P = 0.001$). SMI_{BMI} was inversely associated with the metabolically unhealthy phenotype in overweight/obese men (OR 0.36, 95 % CI 0.18, 0.72, $P = 0.004$), but not in normal-weight men (OR 0.70, 95 % CI 0.34, 1.43, $P = 0.33$). Among women, SMI showed no significant association with the phenotypes. In conclusion, the SMI are inversely associated with the metabolically unhealthy phenotype in men, especially among overweight/obese men.

Key words: Skeletal muscle: Sarcopenia: Dual-energy X-ray absorptiometry: Body composition: Metabolic risk

Obesity is one of the major public health problems in the world and, in recent decades, has become a major risk factor for CVD, due to its association with cardiometabolic disorders such as dyslipidemia, insulin resistance and hypertension⁽¹⁾. However, some obese individuals have a healthier metabolic profile, characterised by normal insulin sensitivity, lipid profile, blood pressure and inflammation markers, despite their elevated fat mass. This condition is defined as metabolically healthy obesity^(1–3). Similarly, normal-weight individuals are not necessarily protected from metabolic disorders associated with obesity and, when those occur, the individuals are characterised as metabolically unhealthy non-obese^(1–3).

Different metabolic phenotypes may be expressed in individuals with the same BMI, which suggests that other determinants besides BMI may influence the clinical outcomes related to cardiometabolic health^(4,5). As an example, research shows that the metabolically healthy phenotype in obese individuals may be a transient condition, influenced by age, environmental factors, lifestyle and body composition changes^(4,6). Thus, identifying factors that can lead to metabolic disorders in normal-weight and overweight individuals could be important to prevent future CVD^(3,7).

Muscle mass is one of the body composition parameters that is closely related to insulin sensitivity and has recently been

Abbreviations: ALM, appendicular lean mass; DXA, dual-energy X-ray absorptiometry; LTPA, leisure-time physical activity; SMI, skeletal mass index; SMM, skeletal muscle mass.

* **Corresponding author:** Cristiane Junqueira de Carvalho, email cristiane.carvalho@ufv.br

associated with metabolic disorders^(8,9). The impact of muscle mass deficit on health began to be studied in the 1990s, when research created skeletal muscle mass (SMM) indices or skeletal mass indices (SMI), based on body composition measurements assessed by dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance^(10,11).

SMI is a measurement of relative muscle mass. This method uses the appendicular lean mass (ALM) or the body SMM adjusted for body size in different ways, for example, using height squared, weight or BMI^(10,11). The first studies with SMI associated the deficit of muscle mass with reduced functional capacity and physical fragility^(10,11). More recently, studies have suggested a relationship between muscle mass deficit and cardiometabolic risk factors such as type 2 diabetes, hypertension, and the metabolic syndrome^(9,12–15).

The association of SMM (by SMI) with the metabolic phenotype of normal-weight and overweight/obese individuals has still not been adequately explored and the results are uncertain^(3,5,7,16–20). However, evidence indicates that it plays a key role in regulating glucose and lipid metabolism and releasing a wide variety of endocrine and autocrine active substances, which might prevent some harmful metabolic conditions^(3,21,22).

The relation between SMM and metabolic phenotypes is divergent and variable among studies. Some studies have found that lower muscle mass is associated with a better metabolic profile in obese individuals and post-menopausal obese women^(23–25). On the other hand, other studies show that in non-obese men and women, higher muscle mass or SMI is significantly associated with better metabolic profile,⁽³⁾ and in non-obese men, muscle mass is inversely associated with metabolically unhealthy phenotype⁽⁷⁾. Kim *et al.*⁽⁵⁾ suggested that the muscle mass deficit may be associated with different metabolic phenotypes according to BMI. Other studies also revealed a variable association of SMI with the phenotypes, depending on sex and age^(7,16,20).

Therefore, the aim of the present study was to evaluate the association of the SMI with the metabolically unhealthy phenotype in normal-weight and overweight/obese adults of both sexes.

Material and methods

Study design and participants

This population-based cross-sectional study was developed with a representative sample of the adult population in Viçosa, Minas Gerais, Brazil, conducted from 2012 to 2014. The study included adults 20–59 years old of both sexes who resided in the urban area of the city. Pregnant women, bedridden individuals, amputees, individuals on whom anthropometric or body composition measurements was impossible and individuals without the ability to answer the questionnaire were not included.

For the sample calculation, the following parameters were considered: reference population of 43 431 adults, 95% confidence level, expected prevalence of low muscle mass of 15%⁽¹⁰⁾, estimated sampling error of 3% and effect of the estimated sampling design at 1.0. There was addition of 20% related to losses or refusals and 10% to control of confounding factors.




Fig. 1. Flow chart of the study. DXA, dual-energy X-ray absorptiometry.

The final calculated sample was 697 adults. In the end, 660 individuals were studied (Fig. 1).

Probabilistic sampling was used without replacement, by double-stage clusters, with census tracts as the first-stage units and households as the second-stage units. A total of thirty census tracts were selected from the ninety-nine existing in the urban area of Viçosa, and in each case the blocks were identified and numbered to specify the order to start work.

The present study was conducted according to the declaration of Helsinki. The research project was approved by the Research Ethics Committee of the Federal University of Viçosa (ref. 02/2013). All participants signed the Informed Consent Form.

Study variables

Sociodemographic variables, health conditions and lifestyle. All of the participants underwent a structured interviewer-administered questionnaire about health conditions and current medication use, as well as sociodemographic and lifestyle variables, namely: age (years), sex (female and male), education (years of study), smoking (non-smoker, smoker and former smoker) and alcohol consumption (drinks per week: 0; 1–7; ≥ 8)⁽²⁶⁾.

To assess the level of leisure-time physical activity (LTPA), the long-form International Physical Activity Questionnaire (IPAQ) version 6 was used⁽²⁷⁾. The LTPA was calculated from the time spent on LTPA in a normal week (IPAQ domain 4). Individuals who scored ≥ 150 min were classified as physically active and those with <150 min as insufficiently active or inactive⁽²⁸⁾.

Anthropometric, clinical and body composition variables.

Weight and height were measured with participants wearing as little clothing as possible and without shoes. Stadiometers were used to measure height and Tanita® digital scales for body weight. BMI was calculated using the weight/height² equation. Waist circumference was measured using a thin inelastic tape measure positioned midway between the iliac crest and the last rib. Blood pressure was measured in duplicate on the same upper limb, with the first measurement after 5 min of rest and the second measure 15 min after the first. The mean of those two measurements was used.

Body composition was assessed by DXA, Lunar Prodigy Advance DXA System (GE Healthcare). All evaluations were performed by the same staff using the standard *Incore Users' Manual* procedure. The precision quality was measured. The CV for lean mass of arms and legs ranged from 0.31 to 0.33%.

The sum of the lean mass of the arms and legs was used to represent the ALM in kilograms. From ALM, we derived the SMI relative to weight (SMI_{weight} : $ALM/weight \times 100$, expressed in %) (29) and the SMI relative to the BMI (SMI_{BMI} : ALM/BMI , expressed in kg/kg per m^2) (30). The body fat percentage (% fat) was also assessed by DXA. For regression analyses, the SMI were standardised in z score.

Biochemical variables. Blood samples were collected after 12 h of fasting. The fasting glucose was determined by the enzymatic method of glucose oxidase (CV 0.52, 1.06%). Total cholesterol (CV 0.59, 2.75%), TAG (CV 0.38, 0.78%), and HDL-cholesterol (CV 0.11, 3.15%) were measured by the Bioclin® kit colorimetric enzymatic method. Plasma insulin was determined by ELISA (Linco Research) (CV 2.1, 2.6%), and insulin resistance was estimated by homoeostasis model assessment: homoeostatic model assessment of insulin resistance = fasting insulin \times fasting glucose/22.5. Ultra-sensitive C-reactive protein was determined by immunoturbidimetry (Bioclin®, Quimbasa Basic Chemistry) (CV 0.79, 4.51%).

Metabolic phenotypes. Participants were classified into four different phenotypes: (a) metabolically healthy normal weight, (b) metabolically unhealthy normal weight, (c) metabolically healthy overweight/obese and (d) metabolically unhealthy overweight/obese.

The definition of phenotypes was based on the criteria of Wildman *et al.* (2), in which individuals are considered metabolically unhealthy when they have two or more of the following cardiometabolic alterations: (1) systolic/diastolic blood pressure $\geq 130/85$ mmHg or use of antihypertensive drugs; (2) TAG ≥ 1.71 mmol/l; (3) HDL < 1.03 mmol/l in men and < 1.29 mmol/l in women or use of lipid lowering medication; (4) fasting glucose ≥ 5.55 mmol/l or use of antidiabetic medication; (5) Insulin resistance: homoeostatic model assessment of insulin resistance $>$ percentile 90 of the population and (6) ultrasensitive C-reactive protein $>$ percentile 90 of the population. According to BMI, individuals were classified as normal weight (18.5 to 24.9 kg/m^2) and overweight/obese (≥ 25 kg/m^2). The latter group included the obese participants (BMI ≥ 30 kg/m^2).

Statistical analysis

Descriptive analysis was presented through tables, as means and standard deviations for continuous variables, and frequencies and percentages for categorical variables, after testing the normal distribution of the variables with the Shapiro–Wilk test, skewness coefficient and graphical analysis. Differences between sexes and between phenotypes were analysed using Student's t test for continuous variables, and Pearson's χ^2 for categorical variables.

Logistic regression was used to estimate the association between the increase of 1 SD of each SMI (standardised

explanatory variables in z score) and the metabolically unhealthy phenotype (variable response). In the adjusted models, the following variables were considered as potential confounders of the studied relationship: age, education, alcoholism, smoking and LTPA. OR with a 95% CI was used as an association measure. Analyses were stratified by sex and BMI. The Hosmer–Lemeshow test was used to verify the final model fit, where P values above 0.05 indicate a good fit of the model and the likelihood ratio test, where a P value less than 0.05 indicates that the explanatory variable significantly predicts the dependent variable.

The interaction between sex and SMI was tested for normal-weight and overweight/obese phenotypes by adding multiplicative interaction terms to the adjusted model. We considered a P value less than 0.10 as significant for interaction terms.

Data analyses were performed using the STATA 13.1 statistical program. Level of significance for all statistical tests was set at 5%.

Results

The sample was composed of 290 men and 370 women, with a mean age of 34.46 years and 37.39 years, respectively. The prevalence of each of the phenotypes was 44.24 (95% CI 40.48, 48.06)% for metabolically healthy normal weight, 10.61 (95% CI 8.47, 13.20)% for metabolically unhealthy normal weight, 21.52 (95% CI 18.53, 24.82)% for metabolically healthy overweight/obese and 23.64 (95% CI 20.54, 27.03)% for metabolically unhealthy overweight/obese. No difference was observed between men and women in the frequency of these phenotypes (Table 1). Analysis of metabolic characteristics that make up the phenotypes indicates that the men had a worse metabolic profile when analysing blood pressure and HDL-cholesterol, while women had the highest ultrasensitive C-reactive protein and homoeostatic model assessment of insulin resistance values (Table 1).

Tables 2 and 3 show that metabolically unhealthy individuals were older than metabolically healthy ones in both sexes, independent of BMI. Among overweight/obese women, those who were metabolically unhealthy were less educated than those who were metabolically healthy. When evaluating SMI among men, those classified as metabolically unhealthy, both normal weight and overweight/obese had lower values than those metabolically healthy. In addition, they had higher body fat percentage and higher waist circumference. No significant differences were observed in the SMI and the body fat percentage in women's metabolic phenotypes. However, metabolically unhealthy women had higher waist circumference.

Among both women and men, the characteristics related to lifestyle, smoking, alcohol consumption, and LTPA were not statistically different between phenotypes.

Among men, after adjusting for age, education, smoking, alcohol consumption and LTPA, SMI_{weight} was inversely associated with the metabolically unhealthy phenotype, both in normal-weight individuals (OR 0.49, 95% CI 0.24, 0.99) and overweight/obese ones (OR 0.32, 95% CI 0.16, 0.64). The SMI_{BMI} was inversely associated with the metabolically



Table 1. Prevalence of phenotypes and metabolic characteristics of the total sample according to sex, Viçosa, Minas Gerais, Brazil, 2012–2014 (Percentages; mean values and standard deviations)

Variables	Total (n 660)		Men (n 290)		Women (n 370)		P*
	Mean	SD	Mean	SD	Mean	SD	
Phenotypes (%)							
MHN	44.24		40.69		47.03		0.10
MUN	10.61		10.69		10.54		
MHO	21.52		25.86		18.11		
MUO	23.64		22.76		24.32		
BMI (kg/m ²)	25.10	4.61	25.31	4.14	24.94	4.95	0.28
us-CRP (mg/l)	1.75	1.90	1.29	1.48	2.13	2.11	<0.001
HOMA-IR	1.87	1.56	1.70	1.36	2.00	1.68	0.01
Mean SBP (mmHg)	118.92	16.02	123.40	13.53	115.38	16.94	<0.001
Mean DBP (mmHg)	76.00	10.66	77.36	10.45	74.93	10.71	0.003
TAG (mmol/l)	1.43	1.05	1.49	1.13	1.38	0.99	0.16
HDL-cholesterol (mmol/l)	1.29	0.38	1.13	0.32	1.40	0.39	<0.001
FG (mmol/l)	4.74	1.12	4.75	0.78	4.73	1.33	0.86

MHN, metabolically healthy normal weight; MUN, metabolically unhealthy normal weight; MHO, metabolically healthy overweight; MUO, metabolically unhealthy overweight; us-CRP, ultra-sensitive C-reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; FG, fasting glucose.

* Student's *t* test or Pearson χ^2 test.

unhealthy phenotype in overweight/obese men (OR 0.36, 95 % CI 0.18, 0.72), but not in normal-weight individuals (OR 0.70, 95 % CI 0.34, 1.43). Women did not exhibit significant association between SMI and metabolic phenotypes (Table 4).

Significant interaction with sex was observed for SMI_{weight} in normal-weight and overweight/obese individuals and for SMI_{IMC} among overweight/obese individuals ($P_{\text{for interaction}} < 0.10$) (Table 4).

Discussion

This is the first Brazilian population-based study that analysed the association between SMI and metabolic phenotypes in normal-weight and overweight/obese adults, which was not limited to the evaluation of individuals with muscle mass deficit.

In the present study, SMI was inversely associated with metabolically unhealthy phenotype among men after adjustment for age, education and life habits, except for SMI_{BMI} in normal-weight men. This association was not found in women, regardless of BMI. In addition, compared with the healthy phenotype, metabolically unhealthy men, regardless of BMI, had lower SMI values and higher fat percentage; unlike women, where we did not find a significant difference.

The results of the present study demonstrate that a lower muscle mass, evidenced by the SMI, is a possible explanation for the existence of the metabolic unhealthy phenotypes in normal-weight and overweight/obese men. The exact explanations and mechanisms involved in the relationship between muscle mass and metabolically unhealthy phenotype have not been fully elucidated. The skeletal muscle is a major metabolically active tissue, closely related to insulin sensitivity and glucose uptake. Furthermore, the skeletal muscle is also considered an active endocrine organ, releasing myokines, stimulating lipolysis and promoting decreased obesity^(3,22,31). In addition, active lifestyle associated with preserved SMM may help the metabolic health of individuals. Thus, greater SMM may be able to maintain individuals' metabolic homeostasis and protect them from a

metabolic unhealthy phenotype. However, the beneficial metabolic effects of SMM may depend on the specific population studied. Our findings do not reveal the influence of muscle mass in the phenotypic expression of adult women.

The absence of an association between SMM and metabolic phenotypes among women has also been reported in studies with a wide age range of women, from childhood to post-menopause, regardless of BMI^(17–20). One study of healthy post-menopausal women suggested a predominant effect of fat distribution on women's metabolic profile, outperforming the contribution of other body composition parameters, like muscle mass, in determining the metabolically unhealthy phenotype⁽¹⁸⁾. In our sample, significantly higher waist circumference values were found in metabolically unhealthy women compared with metabolically healthy women, despite similar values for the percentage of body fat. On the other hand, we did not find a difference in SMI among women with different metabolic phenotypes.

A longitudinal study with Korean adults revealed that greater SMM, assessed by bioimpedance and using SMI_{weight}, plays a protective role against progression from metabolically healthy phenotype to metabolically unhealthy phenotype in normal-weight men and women⁽³⁾. Xia *et al.*⁽¹⁶⁾, using the same method, also demonstrated an inverse association between greater muscle mass and metabolically unhealthy phenotype in Chinese normal-weight females and males. This same study noticed a mitigation of muscle mass association with the metabolically unhealthy phenotype in women over 60 years of age⁽¹⁶⁾.

Therefore, the association between muscle mass and phenotypes clearly varies according to sex, age, SMI assessment methodology and BMI. In addition, metabolic determinants related to body composition in men and women and in obese and non-obese differ significantly between studies^(6,19).

The different tools used to measure muscle mass are possible explanations for divergent results between studies, as some use bioimpedance, magnetic resonance and computed tomography instead of DXA^(3,5,16,25). In addition, the use of the SMI varies between studies^(17,19,20), as there is still no consensus on the most

Table 2. Characteristics of men, according to different phenotypes, Viçosa, Minas Gerais, Brazil, 2012–2014 (Percentages; mean values and standard deviations)

Variables	MHN (n 118)		MUN (n 31)		P*	MHO (n 75)		MUO (n 66)		P†
	Mean	SD	Mean	SD		Mean	SD	Mean	SD	
Age (years)	30.48	9.82	39.58	13.58	<0.001	34.06	10.90	40.80	12.57	<0.001
Education (years)	12.77	4.52	11.90	4.36	0.33	12.13	4.38	11.40	4.62	0.34
LTPA (%)					0.30					0.37
Active	32.20		41.94			29.33		22.73		
Inactive	67.80		58.06			70.67		77.27		
Smoking (%)					0.06					0.06
Non-smoker	74.58		58.06			65.33		60.61		
Smoker	16.13		15.25			18.67		9.09		
Former smoker	10.17		25.81			16.00		30.30		
Alcohol consumption (drinks per week) (%)					0.35					0.73
0	28.81		32.26			30.67		31.82		
1–7	57.63		45.16			45.33		39.39		
≥ 8	13.56		22.58			24.00		28.79		
SMI _{weight} (%)	35.19	3.29	33.41	3.57	0.009	31.85	2.52	29.81	3.31	<0.001
SMI _{BMI} (kg/kg per m ²)	1.08	0.14	1.01	0.15	0.02	0.97	0.12	0.89	0.12	<0.001
Fat %	19.38	6.72	22.90	6.70	0.01	28.71	4.77	32.09	6.24	<0.001
WC (cm)	78.95	5.50	82.61	4.47	<0.001	90.53	6.69	99.90	10.49	<0.001

Muscle mass and metabolic phenotypes

MHN, metabolically healthy normal weight; MUN, metabolically unhealthy normal weight; MHO, metabolically healthy overweight; MUO, metabolically unhealthy overweight; LTPA, leisure-time physical activity; SMI, skeletal mass index; WC, waist circumference.

* Student's *t* test or Pearson χ^2 test among normal-weight individuals (metabolically healthy v. unhealthy).

† Student's *t* test or Pearson χ^2 test among overweight individuals (metabolically healthy v. unhealthy).

Table 3. Characteristics of women, in accordance with the different phenotypes, Viçosa, Minas Gerais, Brazil, 2012–2014 (Percentages; mean values and standard deviations)

Variables	MHN (n 174)		MUN (n 39)		P*	MHO (n 67)		MUO (n 90)		P†
	Mean	SD	Mean	SD		Mean	SD	Mean	SD	
Age (years)	33.38	11.57	38.12	13.35	0.02	37.52	11.04	46.22	9.47	<0.001
Education (years)	12.58	4.07	11.64	4.36	0.20	10.82	4.55	8.91	4.40	0.009
LTPA (%)					0.46					0.15
Active	31.61		25.64			20.90		31.11		
Inactive	68.39		74.36			79.10		68.89		
Smoking (%)					0.17					0.07
Non-smoker	82.76		74.36			68.66		54.44		
Smoker	8.05		17.95			13.43		11.11		
Former smoker	9.20		7.69			17.91		34.44		
Alcohol consumption (drinks per week) (%)					0.12					0.80
0	54.02		69.23			64.18		68.89		
1–7	40.80		30.77			29.85		26.67		
≥8	5.17		0.00			5.97		4.44		
SMI _{weight} (%)	26.87	2.42	26.90	2.77	0.93	23.18	2.19	23.09	2.21	0.79
SMI _{BMI} (kg/kg per m ²)	0.70	0.09	0.68	0.08	0.33	0.59	0.08	0.58	0.07	0.30
Fat %	33.20	4.98	33.10	5.97	0.91	44.31	5.49	43.42	4.48	0.26
WC (cm)	72.28	5.75	75.01	7.02	0.01	87.35	6.76	92.67	8.01	<0.001

MHN, metabolically healthy normal-weight; MUN, metabolically unhealthy normal-weight; MHO, metabolically healthy overweight; MUO, metabolically unhealthy overweight; LTPA, leisure-time physical activity; SMI, skeletal mass index; WC, waist circumference.

* Student's *t* test or Pearson χ^2 test among normal-weight individuals (metabolically healthy v. unhealthy).

† Student's *t* test or Pearson χ^2 test among overweight individuals (metabolically healthy v. unhealthy).

C. J. de Carvalho *et al.*

Table 4. Association between the skeletal mass indices* and metabolically unhealthy phenotype, according to sex and BMI, Viçosa, Minas Gerais, Brazil, 2012–2014† (Odds ratios and 95 % confidence intervals)

	Normal weight (n 362)												P‡
	Men (n 149)						Women (n 213)						
	Crude			Adjusted			Crude			Adjusted			
	OR	95 % CI	P	OR	95 % CI	P	OR	95 % CI	P	OR	95 % CI	P	
SMI _{weight}	0.45	0.24, 0.84	0.01	0.49	0.24, 0.99	0.04	1.03	0.50, 2.09	0.93	1.31	0.58, 2.98	0.51	0.019
SMI _{BMI}	0.49	0.26, 0.93	0.03	0.70	0.34, 1.43	0.33	0.65	0.28, 1.54	0.33	0.88	0.33, 2.37	0.81	0.229
	Overweight (n 298)												P‡
	Men (n 141)						Women (n 157)						
	Crude			Adjusted			Crude			Adjusted			
	OR	95 % CI	P	OR	95 % CI	P	OR	95 % CI	P	OR	95 % CI	P	
SMI _{weight}	0.29	0.15, 0.56	<0.001	0.32	0.16, 0.64	0.001	0.90	0.43, 1.88	0.79	0.93	0.40, 2.17	0.87	0.009
SMI _{BMI}	0.30	0.16, 0.58	<0.001	0.36	0.18, 0.72	0.004	0.63	0.26, 1.51	0.30	1.71	0.58, 5.06	0.32	0.032

SMI, skeletal mass index.

* Standardised in z score.

† Adjustment variables: age, education, alcohol consumption, smoking and level of physical activity in leisure time.

‡ P value for interaction with sex.

appropriate index to determine the degree of muscle mass deficit or which one is most associated with cardiometabolic outcomes⁽³²⁾. Few studies compare these indices and the conclusions are discordant^(13,32,33).

To measure these indices, several definitions are suggested, most of them using the ALM adjusted for height⁽¹⁰⁾, weight⁽²⁹⁾ or BMI⁽³⁰⁾. In the present study, SMI adjusted for body weight and BMI were used, since research that analysed the association and correlation between muscle mass and cardiometabolic diseases has demonstrated the superiority of SMI_{weight} and SMI_{BMI} over SMI_{height}^(15,33–35). The fact that SMI_{height} does not consider adipose mass in its adjustment may result in overestimated muscle mass in overweight and obese individuals and impair muscle mass assessment in the context of cardiometabolic risk in this sample⁽³⁶⁾.

Among normal-weight men in the present study, the association between SMI_{BMI} and the metabolically unhealthy phenotype lost significance in the adjusted models. There are no studies correlating SMI_{BMI} with the metabolic phenotypes in normal-weight or overweight/obese individuals. Likewise, studies of this index in the context of cardiometabolic diseases^(13,33,34,37) are rare, although these studies already indicate the importance of SMI_{BMI} in identifying of the muscle mass deficit and in predicting cardiometabolic risk.

Compared with the rare studies that evaluated the association between SMI or muscle mass and metabolic phenotypes in adults^(3,5,7,16), our study was the only one that could demonstrate the inverse and significant association between SMI and metabolically unhealthy phenotype in overweight/obese men. This relationship among overweight or obese individuals was not observed in other studies.

This finding can be explained by the average age of our sample, which was about 30 to 40 years old, lower than what was reported in previous studies, which was between 50 and 60 years. In the population over 50–60 years, the deleterious effect of adiposity in overweight or obese individuals may be more important

than the beneficial effects of muscle mass⁽³⁾. In addition, myosteatosis, which refers to fat infiltration into muscle tissue, is associated with increased insulin resistance, increased oxidative stress, mitochondrial dysfunction and consequently greater metabolic dysfunction, reducing the benefits of muscle mass in maintaining metabolic balance in elderly and obese individuals^(3,38).

The prevalence of phenotypes has been shown to be quite variable and in the present study they are within the variations of the literature^(2,39,40). The meta-analysis conducted by Wang *et al.*⁽³⁹⁾ found a prevalence of metabolically healthy obese ranging between 1.3 and 25.8 % in the population above 18 years, with highest values among young people and women. A large difference exists between populations worldwide with the highest prevalence of metabolically healthy obese found in the American population⁽³⁹⁾. The prevalence of metabolically unhealthy phenotype with normal weight ranged from 6.6 to 45.9 %, with the highest prevalence observed among older individuals, among men, and Europeans⁽³⁹⁾.

To date, there is no uniform criterion for the diagnosis of metabolic phenotypes. Studies use different definitions of metabolically unhealthy phenotype, which may explain the variability in estimates of phenotype prevalence. It is important to acknowledge that there is no specific definition for the Brazilian population. In this paper, we use the definition proposed by Wildman *et al.*⁽²⁾, which was created from a large epidemiological study, the National Health and Nutrition Examination Surveys (NHANES), 1999–2004, with representativeness of the White, Black and Latin American population in the USA and is the most widely used by researchers.

As in the two meta-analyses cited^(39,40) in the present study, both in normal-weight and overweight/obese individuals, the mean age of metabolically unhealthy phenotype individuals was significantly higher than the healthy phenotype. This finding reinforces the hypothesis that age is one of the factors that favours the onset of metabolic abnormalities in predisposed

individuals and even with the hypothesis of transient metabolic stability in obese individuals^(4,6).

A limitation of the present study is the possibility of reverse causality since it is a cross-sectional study. In addition, dietary information was not evaluated, which could act as a potential confounder. Other characteristics such as muscle quality, muscle strength and physical performance that were not evaluated made it impossible for us to assess the current definition of sarcopenia and its association with nutrition⁽¹¹⁾. The use of a definition of metabolic phenotypes based on a database from the USA can be considered a limitation when studying people in Brazil. Finally, although our study was carried out with a representative sample of adults from a city of Minas Gerais, caution should be taken in extrapolating the results to the whole Brazilian population, taking into account the size of our country and the different characteristics of each region.

In our analysis, higher muscle mass was significantly associated with a lower chance of metabolically unhealthy phenotype expression in normal-weight and overweight/obese men. Given the scarcity of studies on this issue, the real role of muscle mass deficit in determining the metabolic phenotype of individuals must still be clarified.

In conclusion, our results reveal that muscle mass assessed from the SMI adjusted by weight and BMI was inversely associated with metabolically unhealthy phenotype in overweight/obese adult men. In normal-weight men, this association was verified when the SMI_{weight} was used, but not with SMI_{BMI}. These findings corroborate with evidence about the importance in preserving metabolic and muscle health in overweight/obese and normal-weight individuals. With a multidisciplinary approach, including both pharmacological and non-pharmacological interventions like exercises and a nutritional intervention, muscle mass deficit may be an important therapeutic target for reducing adverse profile of metabolically unhealthy patients. However, the lack of association observed between SMI and metabolically unhealthy phenotype in women, the heterogeneous definition of phenotypes, and the divergence in the evaluation of muscle mass indicate the need for further studies to clarify the role of this body compartment in predicting cardiometabolic outcome.

Acknowledgements

We would like to thank all the adults participating in the study, as well as the collaborators of the ESA project. We would also like to thank the health division of the Federal University of Viçosa.

The present study was not sponsored by any pharmaceutical company. The ESA project was supported by the National Council for Scientific and Technological Development – CNPq (grant number 481418/2011-3) and the Foundation for Supporting Research in the State of Minas Gerais – Fapemig (grant number APQ-00296-12).

C. J. C. contributed to the study design and data analyses, wrote the initial draft of the manuscript and assembled the final version. G. Z. L., L. L. J. and A. Q. R. contributed to the study design, analyses design and data analyses and participated in

the approval of the final version of the manuscript. K. J. S. contributed to the data collection and participated in the approval of the final version of the manuscript. A. M. K. and P. F. P. contributed to the study design and participated in the approval of the final version of the manuscript.

The authors declare that there are no conflicts of interest.

References

1. Caleyachetty R, Thomas GN, Toulis KA, *et al.* (2017) Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. *J Am Coll Cardiol* **70**, 1429–1437.
2. Wildman RP, Muntner P, Reynolds K, *et al.* (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. *Arch Intern Med* **168**, 1617–1624.
3. Lee MJ, Hee E, Sung K, *et al.* (2019) Protective role of skeletal muscle mass against progression from metabolically healthy to unhealthy phenotype. *Clin Endocrinol* **90**, 102–113.
4. Gonçalves CG, Glade MJ & Meguid MM (2016) Metabolically healthy obese individuals: key protective factors. *Nutrition* **32**, 14–20.
5. Kim TN, Park MS, Yang SJ, *et al.* (2013) Body size phenotypes and low muscle mass: the Korean Sarcopenic Obesity Study (KSOS). *J Clin Endocrinol Metab* **98**, 811–817.
6. Stefan N, Haring HU, Hu FB, *et al.* (2013) Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. *Lancet Diabetes Endocrinol* **1**, 152–162.
7. Hwang Y-C, Cho I-J, Jeong I-K, *et al.* (2017) Differential association between sarcopenia and metabolic phenotype in Korean young and older adults with and without obesity. *Obesity* **25**, 244–251.
8. Rubio-Ruiz ME, Guamer-Lans V, Pérez-Torres I, *et al.* (2019) Mechanisms underlying metabolic syndrome-related sarcopenia and possible therapeutic measures. *Int J Mol Sci* **20**, 647–670.
9. Zhang H, Lin S, Gao T, *et al.* (2018) Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults: a systematic review and meta-analysis. *Nutrients* **10**, 364–377.
10. Baumgartner RN, Koehler KM, Gallagher D, *et al.* (1998) Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* **147**, 755–763.
11. Cruz-Jentoft AJ, Bahat G, Bauer J, *et al.* (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31.
12. Kim BC, Kim MK, Han K, *et al.* (2015) Low muscle mass is associated with metabolic syndrome only in nonobese young adults: the Korea National Health and Nutrition Examination Survey 2008–2010. *Nutr Res* **35**, 1070–1078.
13. Scott D, Park MS, Kim TN, *et al.* (2016) Associations of low muscle mass and the metabolic syndrome in Caucasian and Asian middle-aged and older adults. *J Nutr Heal Aging* **20**, 248–255.
14. Kwon SS, Lee S-G, Lee Y, *et al.* (2016) Homeostasis model assessment of insulin resistance in a general adult population in Korea: additive association of sarcopenia and obesity with insulin resistance. *Clin Endocrinol* **86**, 44–51.
15. Lim S, Kim JH, Kang SM, *et al.* (2010) Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging. *Diabetes Care* **33**, 1652–1654.
16. Xia L, Dong F, Gong H, *et al.* (2017) Association between indices of body composition and abnormal metabolic phenotype in

- normal weight Chinese adults. *Int J Environ Res Public Health* **14**, 391.
17. Poggiogalle E, Lubrano C, Gnassi L, *et al.* (2019) The decline in muscle strength and muscle quality in relation to metabolic derangements in adult women with obesity. *Clin Nutr* **38**, 2430–2435.
 18. Peppas M, Koliaki C, Boutati E, *et al.* (2014) Association of lean body mass with cardiometabolic risk factors in healthy postmenopausal women. *Obesity* **22**, 828–835.
 19. Peppas M, Koliaki C, Papaefstathiou A, *et al.* (2013) Body composition determinants of metabolic phenotypes of obesity in nonobese and obese postmenopausal women. *Obesity* **21**, 1807–1814.
 20. Ding WQ, Liu JT, Shang YX, *et al.* (2018) DXA-measured visceral fat mass and lean body mass reflect abnormal metabolic phenotypes among some obese and non-obese Chinese children and adolescents. *Nutr Metab Cardiovasc Dis* **28**, 618–628.
 21. Kim J-H, Cho JJ & Park YS (2015) Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. *J Korean Med Sci* **30**, 264–271.
 22. Stump CS, Henriksen EJ, Wei Y, *et al.* (2006) The metabolic syndrome: role of skeletal muscle metabolism. *Ann Med* **38**, 389–402.
 23. Barbat-Artigas S, Filion M-E, Plouffe S, *et al.* (2012) Muscle quality as a potential explanation of the metabolically healthy but obese and sarcopenic obese paradoxes. *Metab Syndr Relat Disord* **10**, 117–122.
 24. Primeau V, Coderre L, Karelis AD, *et al.* (2010) Characterizing the profile of obese patients who are metabolically healthy. *Int J Obes* **35**, 971–981.
 25. Estrella ML, Pirtzada A, Durazo-Arvizu RA, *et al.* (2019) Correlates of and body composition measures associated with metabolically healthy obesity phenotype in hispanic/latino women and men: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *J Obes* **2019**, 1251456.
 26. Furlan-Viebig R & Pastor-Valero M (2004) Development of a food frequency questionnaire to study diet and non-communicable diseases in adult population. *Rev Saude Publica* **38**, 581–584.
 27. Pardini R, Matsudo S, Araújo T, *et al.* (2001) Validação do questionário internacional de nível de atividade física (IPAQ-versão 6): estudo piloto em adultos jovens brasileiros (Validation of the international physical activity level questionnaire (IPAQ-version 6): a pilot study in young Brazilian adults). *Rev Bras Ciên e Mov* **9**, 45–51.
 28. Haskell WL, Lee IM, Pate RR, *et al.* (2007) Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc* **39**, 1423–1434.
 29. Janssen I, Heymsfield SB & Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J Am Geriatr Soc* **50**, 889–896.
 30. Studenski SA, Peters KW, Alley DE, *et al.* (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol - Ser A Biol Sci Med Sci* **69**, 547–558.
 31. Tournadre A, Vial G, Capel F, *et al.* (2019) Sarcopenia. *Joint Bone Spine* **86**, 309–314.
 32. Kim KM, Jang HC & Lim S. (2016) Differences among skeletal muscle mass indices derived from height-, weight-, and body mass index-adjusted models in assessing sarcopenia. *Korean J Intern Med* **31**, 643–650.
 33. Furushima T, Miyachi M, Iemitsu M, *et al.* (2017) Comparison between clinical significance of height-adjusted and weight-adjusted appendicular skeletal muscle mass. *J Physiol Anthropol* **36**, 15.
 34. Kim TN, Park MS, Lee EJ, *et al.* (2017) Comparisons of three different methods for defining sarcopenia: an aspect of cardiometabolic risk. *Sci Rep* **7**, 6491–6500.
 35. Lee J, Hong Y, Shin HJ, *et al.* (2016) Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. *J Prev Med Public Heal* **49**, 35–44.
 36. Newman AB, Kupelian V, Visser M, *et al.* (2003) Sarcopenia: alternative definitions and associations with lower extremity function. *J Am Geriatr Soc* **51**, 1602–1609.
 37. Kim G, Lee SE, Jun JE, *et al.* (2018) Increase in relative skeletal muscle mass over time and its inverse association with metabolic syndrome development: a 7-year retrospective cohort study. *Cardiovasc Diabetol* **17**, 23–36.
 38. Taaffe DR, Henwood TR, Nalls MA, *et al.* (2009) Alterations in muscle attenuation following detraining and retraining in resistance trained older adults. *Gerontology* **55**, 217–223.
 39. Wang B, Zhuang R, Luo X, *et al.* (2015) Prevalence of metabolically healthy obese and metabolically obese but normal weight in adults worldwide: a meta-analysis. *Horm Metab Res* **47**, 839–845.
 40. Lin H, Zhang L, Zheng R, *et al.* (2017) The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis. *Medicine* **96**, e8838.